Edge Therapeutics, which is developing formulations of existing therapies for ruptured brain aneurysms, filed on Friday with the SEC to raise up to $115 million in an initial public offering.
The Berkeley Heights, NJ-based company, which was founded in 2009, plans to list on the Nasdaq under the symbol EDGE. Edge Therapeutics initially filed confidentially on 3/21/2014. Leerink Partners and Credit Suisse are the joint bookrunners on the deal. No pricing terms were disclosed.
